The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Phase III study of leniolisib in patients with activated PI3K delta syndrome
V. Koneti Rao, MD, FRCPA, National Institute of Allergy and Infectious Diseases, Bethesda, MD, shares some results from a Phase III study evaluating the use of leniolisib, a delta PI3K inhibitor, in patients with activated PI3K delta syndrome (APDS/PASLI). Dr Rao first provides some detailed information on symptoms and clinical manifestations of this rare disease, and then goes on to discuss the efficacy of leniolisib in these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
